|
Market Closed -
Nasdaq
16:00:00 2026-09-03 EDT
|
5-day change | 1st Jan Change | ||
| 22.80 USD | -0.22% |
|
-7.58% | +38.10% |
| 08-25 | B. Riley Adjusts Denali Therapeutics Price Target to $35 From $30, Maintains Buy Rating | MT |
| 08-24 | FDA places clinical hold on Regenxbio's gene therapy for Hunter Syndrome | RE |
Company Valuation: Denali Therapeutics Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 5,447 | 3,777 | 2,966 | 2,933 | 2,578 | 3,645 | - | - |
| Change | - | -30.66% | -21.48% | -1.1% | -12.1% | 41.36% | - | - |
| Enterprise Value (EV) 1 | 4,581 | 2,441 | 1,931 | 2,101 | 1,710 | 2,936 | 2,896 | 2,776 |
| Change | - | -46.72% | -20.88% | 8.78% | -18.59% | 71.67% | -1.37% | -4.13% |
| P/E | -18.7x | -10.7x | -20.2x | -7.93x | -5.56x | -9.85x | -9.89x | -13.4x |
| PBR | 5.67x | 3.63x | 2.86x | 2.39x | 2.54x | 6.11x | 8.43x | 8.6x |
| PEG | - | -1.22x | 0.3x | -0x | -0.4x | 0.4x | 23.04x | 0.5x |
| Capitalization / Revenue | 112x | 34.8x | 8.97x | - | - | 72.5x | 28.7x | 13.1x |
| EV / Revenue | 94.1x | 22.5x | 5.84x | - | - | 58.4x | 22.8x | 9.94x |
| EV / EBITDA | -16x | -7.39x | -10.7x | -4.38x | -3.1x | -5.86x | -6.19x | -7.16x |
| EV / EBIT | -15.5x | -7.16x | -9.82x | -4.31x | -3.08x | -5.76x | -6.05x | -7.6x |
| EV / FCF | -20.8x | -9.3x | -5.21x | -5.78x | -4.05x | -6.47x | 18.8x | -43.2x |
| FCF Yield | -4.8% | -10.8% | -19.2% | -17.3% | -24.7% | -15.5% | 5.31% | -2.32% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -2.39 | -2.6 | -1.06 | -2.57 | -2.97 | -2.315 | -2.305 | -1.702 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 48.66 | 108.5 | 330.5 | - | - | 50.26 | 126.9 | 279.3 |
| EBITDA 1 | -287.2 | -330.4 | -180 | -479.5 | -552.5 | -501.1 | -467.5 | -387.7 |
| EBIT 1 | -295.8 | -340.7 | -196.7 | -487.3 | -555.3 | -509.9 | -478.3 | -365.3 |
| Net income 1 | -290.6 | -326 | -145.2 | -422.8 | -512.5 | -454.5 | -452.5 | -352.6 |
| Net Debt 1 | -865.4 | -1,336 | -1,035 | -832.3 | -867.9 | -708.4 | -748.7 | -868.4 |
| Reference price 2 | 44.60 | 27.81 | 21.46 | 20.38 | 16.51 | 22.80 | 22.80 | 22.80 |
| Nbr of stocks (in thousands) | 122,126 | 135,814 | 138,197 | 143,922 | 156,158 | 159,847 | - | - |
| Announcement Date | 2/28/22 | 2/27/23 | 2/27/24 | 2/27/25 | 2/26/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -9.87x | 58.58x | -5.87x | -.--% | 3.65B | |
| 20.44x | 7.17x | 14.49x | 1.43% | 68.87B | |
| 37.07x | 9.67x | 29.5x | 0.04% | 65.29B | |
| -77.51x | 14.96x | -72.15x | -.--% | 27.65B | |
| 29.76x | 6.36x | 16.52x | -.--% | 25.77B | |
| -15.9x | 6.16x | -7.74x | -.--% | 26.08B | |
| 27.51x | 5.14x | 17.12x | -.--% | 20.14B | |
| 49.22x | 18.16x | 36.83x | 0.31% | 17.03B | |
| 1298.7x | 37.56x | 819.65x | -.--% | 15.03B | |
| 18.08x | 5.39x | 12.58x | -.--% | 14.5B | |
| Average | 137.75x | 16.92x | 86.09x | 0.18% | 28.4B | |
| Weighted average by Cap. | 81.58x | 11.03x | 51.41x | 0.37% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- DNLI Stock
- Valuation Denali Therapeutics Inc.
Select your edition
All financial news and data tailored to specific country editions
